… in CD than in ulcerative colitis (UC). Notwithstanding that prior exposure to a TNF antagonist
… help overcome the current gap in personalised medicine for inflammatory bowel disease. …

… Along with ulcerative colitis, Crohn’s disease (CD) is one of the two inflammatory bowel
diseases (IBDs). It is a chronic disease in which severe inflammation of the digestive tract results …

… Interestingly, only those patients who were persistently positive for AVAs experienced a
meaningful decrease in vedolizumab exposure and did not achieve clinical remission at the end …

… All Crohn's disease patients treated with ustekinumab or vedolizumab after exposure to
at least one anti-TNF agent were included from two referral centres. Primary endpoint was …

… (UC), the two major types of inflammatory bowel disease (IBD), are chronic remitting/…
exposure. No increased risk of any infection or serious infection was associated with VDZ exposure. …

… UST has shown good efficacy and safety similar to anti-TNF agents and vedolizumab in the
… impact of vedolizumab on postoperative outcomes suggested vedolizumab exposure was …

… vedolizumab infusion. For patients receiving ustekinumab, Harvey-Bradshaw Index was
monitored by inflammatory bowel disease … anti-TNF-exposed patients showed no difference in …

… revolutionized the medical management of inflammatory bowel disease (IBD). Despite these
… case matching vedolizumab exposed, anti-TNF exposed and no biologic exposed patients. …

… vedolizumab (VDZ) therapy on postoperative complications in inflammatory bowel disease
(IBD) … During the operation, the time of intestinal exposure should also be reduced to keep the …

… In post-marketing safety studies, joint-related events, including mostly arthralgia, were
infrequent non-serious events [526 events during 46798 patient-years of vedolizumab exposure; …